JP5734957B2 - ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 - Google Patents

ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 Download PDF

Info

Publication number
JP5734957B2
JP5734957B2 JP2012507354A JP2012507354A JP5734957B2 JP 5734957 B2 JP5734957 B2 JP 5734957B2 JP 2012507354 A JP2012507354 A JP 2012507354A JP 2012507354 A JP2012507354 A JP 2012507354A JP 5734957 B2 JP5734957 B2 JP 5734957B2
Authority
JP
Japan
Prior art keywords
dopamine
compounds
item
alkyl
arch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012507354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524796A (ja
JP2012524796A5 (https=
Inventor
ニコルス，デイヴィッド，アール
ワッツ，ヴァル，ジョセフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2012524796A publication Critical patent/JP2012524796A/ja
Publication of JP2012524796A5 publication Critical patent/JP2012524796A5/ja
Application granted granted Critical
Publication of JP5734957B2 publication Critical patent/JP5734957B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2012507354A 2009-04-21 2010-04-21 ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用 Expired - Fee Related JP5734957B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17127309P 2009-04-21 2009-04-21
US61/171,273 2009-04-21
PCT/US2010/031916 WO2010124005A1 (en) 2009-04-21 2010-04-21 Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor

Publications (3)

Publication Number Publication Date
JP2012524796A JP2012524796A (ja) 2012-10-18
JP2012524796A5 JP2012524796A5 (https=) 2013-06-06
JP5734957B2 true JP5734957B2 (ja) 2015-06-17

Family

ID=43011462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507354A Expired - Fee Related JP5734957B2 (ja) 2009-04-21 2010-04-21 ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用

Country Status (4)

Country Link
US (1) US9359303B2 (https=)
EP (1) EP2421862B1 (https=)
JP (1) JP5734957B2 (https=)
WO (1) WO2010124005A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107011301B (zh) * 2017-05-27 2019-06-28 山东省联合农药工业有限公司 一种2-（2-甲氧基苯基）-5-氧代四氢呋喃-3-羧酸的制备方法
CA3148598A1 (en) 2019-07-30 2021-02-04 Mayo Foundation For Medical Education And Research Compounds and methods for treating fibrotic pathologies
US20240043396A1 (en) * 2021-01-29 2024-02-08 Mayo Foundation For Medical Education And Research Methods of treating ocular fibrotic pathologies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
DK297275A (da) 1974-08-07 1976-02-08 Aspro Nicholas Ltd Isoquinolinderivater
US3939165A (en) 1974-11-14 1976-02-17 Morton-Norwich Products, Inc. 5,6,6A,6B,7,8-Hexahydrobenz[a]phenanthridine hydrochloride
US4346090A (en) 1977-07-21 1982-08-24 Ayerst, Mckenna & Harrison Ltd. 13-Chloro-benzocycloheptapyridoisoquinolines and use as neuroleptics
CA1270253A (en) 1981-06-18 1990-06-12 John L. Neumeyer R(-)-10,11-alkylenedioxy-n-alkylnorapomorphine
US4678791A (en) * 1985-05-07 1987-07-07 Pennwalt Corporation 6-phenyl-1,2-3,4,4a,5-6,10b-octahydrobenz(h)isoquinolines useful for treating depression
US4737503A (en) 1986-10-08 1988-04-12 Vipont Laboratories, Inc. Method for inhibiting the release of histamine
US5047536A (en) 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) * 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
GB8917333D0 (en) 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
US5180733A (en) 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5635506A (en) 1990-06-26 1997-06-03 Research Corporation Technologies, Inc. 1, 2-dihydro-3H-dibenzisoquinoline-1,3-dione anticancer agents
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
US5266702A (en) 1990-09-19 1993-11-30 Council Of Scientific & Industrial Research 1,3-oxazoline compounds useful as anionic initiators suitable for polymerization of vinyl polymers
US5216018A (en) 1992-02-14 1993-06-01 Du Pont Merck Pharmaceutical Company Hydroisoindolines and hydroisoquinolines as psychotropic
WO1993024462A1 (en) 1992-05-26 1993-12-09 Purdue Research Foundation Substituted-hexahydrobenzo[a]phenanthridines
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
FI954738A7 (fi) 1993-04-06 1995-12-05 Abbott Lab Tetrasykliini yhdisteet dopamiiniagonisteina
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
US5554621A (en) * 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
MX9801179A (es) 1995-08-18 1998-04-30 Purdue Research Foundation Isoquinolinas fusionadas, novedosas como ligandos del receptor de dopamina.
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
AU4536599A (en) 1999-06-21 2001-01-09 Geochemistry Research Limited Metal-rich silica products from geothermal and synthetic aqueous systems nen wie
US6733797B1 (en) 2000-11-15 2004-05-11 William K. Summers Neuroceutical for improving memory and cognitive abilities
WO2002056875A2 (en) 2001-01-16 2002-07-25 Purdue Research Foundation Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
DE60323339D1 (de) 2002-02-15 2008-10-16 Darpharma Inc Monoester und asymmetrisch substituierte diester prodrugs der dopamin-d1-rezeptor-agonisten
EP1699450A4 (en) 2003-12-23 2009-11-11 Darpharma Inc Simultaneous administration of dopamine receptor bindings
US20070254906A1 (en) 2004-07-21 2007-11-01 Darpharma, Inc. Method of Administration of Dopamine Receptor Agonists
US7563805B2 (en) 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
PE20070549A1 (es) 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
NZ570606A (en) 2006-02-21 2011-11-25 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use

Also Published As

Publication number Publication date
JP2012524796A (ja) 2012-10-18
US9359303B2 (en) 2016-06-07
EP2421862A1 (en) 2012-02-29
US20120041018A1 (en) 2012-02-16
EP2421862B1 (en) 2014-06-11
WO2010124005A1 (en) 2010-10-28
EP2421862A4 (en) 2012-12-26

Similar Documents

Publication Publication Date Title
EP2187888B1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
JP2024026104A (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
JP2017002085A (ja) スピロ−オキシインドール化合物のエナンチオマーおよび治療剤としてのその使用
TW200404808A (en) Pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds therefor
CA3019012A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
KR20080007250A (ko) 스피로헤테로시클릭 화합물 및 이들의 치료제로서의 용도
US20030105096A1 (en) Serotonin transport inhibitors
TW201118069A (en) Spirolactam derivatives and uses of same
JP5734957B2 (ja) ドーパミンレセプターのオクタヒドロベンゾイソキノリンモジュレーター及びその使用
EP2233140A1 (en) Bicyclic amides for enhancing glutamatergic synaptic responses
US20150045435A1 (en) Compounds and methods for treating diabetes
JP3939369B2 (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
ES2605466T3 (es) Compuesto de benzacepina
KR20020038947A (ko) 씨엔에스 질환에 대한 카보닐아미노 유도체의 용도
JP2025536344A (ja) ｓＧＣ刺激剤でのミトコンドリア疾患の処置
TW202321258A (zh) 氧雜螺環類衍生物、製備方法及其用途
AU2007216994A2 (en) Trans-fused chromenoisoquinolines, synthesis and methods for use
JP6242811B2 (ja) 新規なオクタヒドロピリドキナゾリン誘導体、それを含有する医薬組成物およびそれらの用途
KR102721799B1 (ko) 신규한 카나비디올 유도체, 이의 제조 방법 및 이를 포함하는 파킨슨병의 예방 또는 치료용 조성물
HK40119317A (zh) Kv7通道激活剂组合物和使用方法
HK40120047A (zh) Kv7通道激活剂组合物和使用方法
HK40119318A (zh) Kv7通道激活剂组合物和使用方法
HK40118422A (zh) Kv7通道激活剂组合物和使用方法
HK40119631A (zh) Kv7通道激活剂组合物和使用方法
JP2016011291A (ja) 新規なドパミンｄ２受容体アゴニスト

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140702

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150415

R150 Certificate of patent or registration of utility model

Ref document number: 5734957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees